Claude M. Wischik

Aberdeen, SCT AB252ZD, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 78 publications

A proteomic analysis of the PHF-forming tau fragment (tau297-391) following uptake into differentiated human neuronal SHSY5Y cells.

A proteomic analysis of the PHF-forming tau fragment (tau297-391) following uptake into differentiated human neuronal SHSY5Y cells.

Journal: Bioscience reports

Published: May 12, 2026

Diagnostic impact of tau versus amyloid PET in patients with cognitive symptoms.

Diagnostic impact of tau versus amyloid PET in patients with cognitive symptoms.

Journal: Brain : a journal of neurology

Published: January 26, 2026

Inhibiting Disulfide Bonding in Truncated Tau297-391 Results in Enhanced Self-Assembly of Tau into Seed-Competent Assemblies.

Inhibiting Disulfide Bonding in Truncated Tau297-391 Results in Enhanced Self-Assembly of Tau into Seed-Competent Assemblies.

Journal: ACS chemical neuroscience

Published: December 10, 2025

Assessment of clinical and neuroimaging efficacy of treatment targeting tau pathology in mild cognitive impairment and mild to moderate Alzheimer's disease with hydromethylthionine mesylate using external control data.

Assessment of clinical and neuroimaging efficacy of treatment targeting tau pathology in mild cognitive impairment and mild to moderate Alzheimer's disease with hydromethylthionine mesylate using external control data.

Journal: The journal of prevention of Alzheimer's disease

Published: October 07, 2025

Clinical, imaging and blood biomarker outcomes in a Phase 3 clinical trial of tau aggregation inhibitor hydromethylthionine mesylate in mild cognitive impairment and mild to moderate dementia due to Alzheimer's disease.

Clinical, imaging and blood biomarker outcomes in a Phase 3 clinical trial of tau aggregation inhibitor hydromethylthionine mesylate in mild cognitive impairment and mild to moderate dementia due to Alzheimer's disease.

Journal: The journal of prevention of Alzheimer's disease

Published: October 01, 2025

Timing matters: early administration of a high-affinity antibody targeting the tau repeat domain prevents aggregation in a mouse tauopathy model.

Timing matters: early administration of a high-affinity antibody targeting the tau repeat domain prevents aggregation in a mouse tauopathy model.

Journal: Alzheimer's research & therapy

Published: September 03, 2025

Proteomic and non-proteomic changes of presynaptic proteins in animal models of Alzheimer's disease: A meta-analysis 2015-2023.

Proteomic and non-proteomic changes of presynaptic proteins in animal models of Alzheimer's disease: A meta-analysis 2015-2023.

Journal: Journal of Alzheimer's disease : JAD

Published: August 01, 2025

Quantification of plasma tau species containing the proline-rich region as a biomarker in Alzheimer's disease.

Quantification of plasma tau species containing the proline-rich region as a biomarker in Alzheimer's disease.

Journal: Scientific reports

Published: July 23, 2025

Effects of hydromethylthionine mesylate and rivastigmine in a pharmacological mouse model of Alzheimer's disease.

Effects of hydromethylthionine mesylate and rivastigmine in a pharmacological mouse model of Alzheimer's disease.

Journal: Behavioural pharmacology

Published: June 23, 2025

Hypertension is the Main Vascular Risk Factor for Cognitive Impairment, Microvascular Pathology and Brain Atrophy in Alzheimer's Disease.

Hypertension is the Main Vascular Risk Factor for Cognitive Impairment, Microvascular Pathology and Brain Atrophy in Alzheimer's Disease.

Journal: Current Alzheimer research

Published: April 18, 2025

Hypertension is the Main Vascular Risk Factor for Cognitive Impairment, Microvascular Pathology and Brain Atrophy in Alzheimer's Disease.

Hypertension is the Main Vascular Risk Factor for Cognitive Impairment, Microvascular Pathology and Brain Atrophy in Alzheimer's Disease.

Journal: Current Alzheimer research

Published: April 18, 2025

Neurofilament light (NfL) chain levels predict clinical decline in Alzheimer's disease: A systematic review and meta-analysis.

Neurofilament light (NfL) chain levels predict clinical decline in Alzheimer's disease: A systematic review and meta-analysis.

Journal: Journal of Alzheimer's disease reports

Published: April 10, 2025

Showing 1-12 of 78

Last Updated: 09/26/2026